Testing a New Imaging Agent to Identify Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: HER-2 Positive Malignant Carcinoma of Breast|HER-2 Protein Overexpression|HER2-positive Metastatic Breast Cancer
Interventions: COMBINATION_PRODUCT: 89Zr-ss-pertuzumab PET/CT
Sponsor: Memorial Sloan Kettering Cancer Center
Collaborators: National Institutes of Health (NIH)